95% of stroke patients don’t receive treatment today. This is due to the lack of fast and accurate diagnosis.

POCKiT diagnostics has been working since 2017 to develop a novel biomarker panel for stroke subtype differentiation.

“There are many delays in the stroke treatment workflow. Even before the patient gets to the hospital there can be delays in symptom recognition, contacting emergency services and getting the patient to a hospital that provides thrombectomy” 
– Goyal et al. Radiology 2016 –

“Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest. The demand for newer techniques to deliver individualized information on-site for incorporation into a time-sensitive work-flow has become greater“ 
– Harpaz et al. Biosensors 2017 –

Our challenge

POCKiT diagnostics is a Cambridge-based company born in 2017. Since the beginning our challenge was clear: we wanted to build a novel biomarker panel for stroke subtype differentiation. Stroke affects 16,000,000 people each year. 33% of patients will die and 90% of survivors will have a disability for the rest of their lives. Although stroke biomarkers have been investigated for several years, a biomarker panel able to identify stroke subtype has not been applied to the clinic yet. In 2018, we performed a double-blind retrospective clinical study where we discovered a novel biomarker panel with high accuracy that could increase patients treatment from 4% to 40%.

Join our Clinical Trials

We are currently validating our biomarker panel in independent stroke patient cohorts. This study will be conducted in different sites, across the globe.


Great support – 
great network

POCKiT diagnostics has been awarded with a £1,000,000 grant from the United Kingdom government to finish an extensive clinical study in order to achieve regulatory approval. This collaborative effort started in December 2018 and involved several partners including hospitals, biobanks, universities, enterprises and clinicians from UK and USA, counting in our team the UK representative for European stroke guidelines. Also, we have already started our sample collection in partnership with Newcastle hospitals. At the moment, we are willing to collaborate with hospitals, research centres, researchers and clinicians to realise our clinical trial. Our goal is to achieve market approval in 2020.


We have collected incredible traction in a short amount of time through public funding, startup competitions, and university awards.

Project Lead
Innovate UK

£975,000 Awarded by Innovate UK in December 2018

Innovate UK is the operating name of the Technology Strategy Board, UK’s innovation agency. It is a non-departmental public body operating at arm’s length from the Government as part of the United Kingdom Research and Innovation organisation.

2018 Santander Universities Entrepreneurship Award

In November 2018 Ana Botin, Chair of Santander Bank, gave us the Santander Runner-up award out of more than 1,000 applications in all the United Kingdom. The award consisted in a cash prize of £15,000 and a free internship student. POCKiT diagnostics represented University of Cambridge at this event.

Our Team

Gonzalo Ladreda

Founder and CEO

Involved to entrepreneurship since he is 19 years old. Leading a £1,000,000 grant from UK government. Member of the Accelerate Program at Cambridge Judge Business School.

Marcos Ladreda

Founder and CSO

Biomedical Scientist. Expert in rapid diagnostic tests and amplification systems. Leading technology development.

Edoardo Gaude

Founder and CIO

PhD from University of Cambridge. Expert in Biomarker research and discovery. Author of >40 publications.

Scientific Advisory Board

Christopher Price

Advisor – UK representative for European pre-hospital stroke management guidelines.

Jason Chen

Advisor – Neuroscientist, Y Combinator Entrepreneur. Jason raised over $100 Million for startups.

Joshua Bernstock

Advisor – Neurosurgery fellow at
Harvard Medical School

Contact us

If you want to know more about POCKiT diagnostics, please fill the form below.